National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 9786-9787 [2020-03334]
Download as PDF
<![CDATA[
lotter on DSKBCFDHB2PROD with NOTICES
9786
Federal Register / Vol. 85, No. 34 / Thursday, February 20, 2020 / Notices
determination that an advisory board
should be convened to recommend
whether, with respect to research
involving human fetal tissue (HFT)
proposed in NIH grant and cooperative
agreement applications and R&D
contract proposals, described in the NIH
Guide Notice NOT–OD–19–128, the
Secretary should withhold funds or not
withhold funds because of ethical
considerations; (2) his intent to convene
such an advisory board; and (3) the
establishment of the NIH Human Fetal
Tissue Ethics Advisory Board—FY
2020. NIH Human Fetal Tissue Ethics
Advisory Board—FY 2020 is governed
by the Federal Advisory Committee Act
(5 U.S.C. App.), which sets forth
standards for the formation and use of
advisory committees. The number of
meetings to be held by the Board will
depend on the number of relevant NIH
grant and cooperative agreement
applications and R&D contract
proposals pending the Board’s
consideration. Meetings will be open to
the public except as determined
otherwise by the Secretary in
accordance with subsection (c) of
section 552b of Title 5 U.S.C. Notice of
all meetings will be given to the public.
In accordance with section
492A(5)(B)(ii) of the PHS Act, no later
than 180 days after the date on which
this notice is published in the Federal
Register, the Board will submit to the
Secretary, the Committee on Energy and
Commerce of the House of
Representatives, and the Committee on
Health, Education, Labor and Pensions
of the Senate, a report describing the
findings of the Board regarding the
project(s) of research involved and
recommendations regarding whether the
Secretary should or should not withhold
funds for the project(s). As required by
section 492A(b)(5)(K) of the PHS Act,
the Ethics Board will terminate 30 days
after the date on which the required
report is submitted to the Secretary, the
Committee on Energy and Commerce of
the House of Representatives, and the
Committee on Health, Education, Labor
and Pensions of the Senate.
Notice of Establishment: Pursuant to
the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), the Secretary
of Health and Human Services (HHS),
announces the establishment of the NIH
Human Fetal Tissue Research Ethics
Advisory Board—FY 2020, as
authorized by section 492A of the
Public Health Service (PHS) Act, 42
U.S.C. 289a–1, as amended.
The Ethics Board will advise, consult
with, and make recommendations to,
the Secretary of Health and Human
Services (Secretary) regarding the ethics
of research involving human fetal tissue
VerDate Sep<11>2014
19:48 Feb 19, 2020
Jkt 250001
(HFT) proposed in NIH grant and
cooperative agreement applications and
R&D contract proposals, described in
the NIH Guide Notice NOT–OD–19–128.
Recommendations will address whether
the Secretary should withhold funds or
not withhold funds from a proposed
project because of ethical
considerations. In providing advice and
recommendations on these matters, the
Ethics Board will consider, among other
things, the use of alternative models,
and review and verify the core ethical
principles and procedures used in the
process to obtain written voluntary
informed consent for the donation of the
tissue. The ethical considerations the
Ethics Board should consider are those
related to whether the nature of the
research involved is such that it is
unethical to conduct or support the
research.
Notice of Intent To Convene:
Consistent with section 492A of the PHS
Act, this announcement outlines the
intention of the HHS Secretary to
convene the Ethics Board and solicits
nominations for the individuals who
should be considered for appointment
to the Board. The Secretary will
consider such recommendations in
making appointments to the Board.
Call for Nominations: The Board will
be composed of 15 individuals who are
not federal employees. Section
492A(b)(5)(C) of the PHS Act establishes
certain requirements for the
composition of the Board. The
appointed members of the Board will
include no fewer than one attorney; no
fewer than one ethicist; no fewer than
one practicing physician; and no fewer
than one theologian. No fewer than onethird, and no more than one-half of the
appointed members will be scientists
with substantial accomplishments in
biomedical or behavioral research.
Interested individuals may selfnominate or be nominated by another
individual or organization. The
following information may be included
in the package of materials submitted
for each individual being nominated for
consideration: (1) A letter of nomination
stating the name, affiliation, and contact
information for the nominee, the basis
for the nomination (i.e., the specific
attributes, perspectives, and/or skills the
individual possesses that would benefit
the workings of the Ethics Board), and
the nominee’s field(s) of expertise; (2) a
biographical sketch of the nominee; (3)
the name, address, daytime telephone
number, and email address at which the
nominator can be contacted; (4) a
current copy of the nominee’s
curriculum vitae; and (5) the category of
Board member the nominee would fill
(i.e., attorney, ethicist, practicing
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
physician, theologian, or scientist with
substantial accomplishments in
biomedical or behavioral research).
Nomination packages may be submitted
directly by the individual being
nominated or by the person/
organization recommending the
candidate.
Dated: February 12, 2020.
Alex M. Azar II,
Secretary.
[FR Doc. 2020–03302 Filed 2–19–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; ZAI1–EC–D–M1, NIAID
Research Education Program (R25) Mar 31,
2020.
Date: March 31, 2020.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Eleazar Cohen, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institute of Health, 5601
Fishers Lane, Room 3G62A, Bethesda, MD
20892, (240) 669–5081, ecohen@
niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
E:\FR\FM\20FEN1.SGM
20FEN1
Federal Register / Vol. 85, No. 34 / Thursday, February 20, 2020 / Notices
Dated: February 13, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2020–03334 Filed 2–19–20; 8:45 am]
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
lotter on DSKBCFDHB2PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Clinical Trail
Planning Grant (R34 Clinical Trail Not
Allowed) and Implementation Cooperative
Agreement (U01 Clinical Trial Required).
Date: March 11, 2020.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G31B,
Rockville, MD 20892 (Telephone Conference
Call).
Contact Person: James T. Snyder, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3G31B, Rockville, MD
20892, (240) 669–5060, james.snyder@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: February 13, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–03335 Filed 2–19–20; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
19:48 Feb 19, 2020
Jkt 250001
National Institutes of Health
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; ZAI1 EC–A–C1, NIH/NIAID
059 (Diagnostics to Enable Malaria and
Neglected Tropical Diseases (NTDs)
Elimination), Mar 19, 2020.
Date: March 19, 2020.
Time: 10:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Eleazar Cohen, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institute of Health, 5601
Fishers Lane, Room 3G62A, Bethesda, MD
20892, (240) 669–5081, ecohen@
niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: February 13, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–03336 Filed 2–19–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
9787
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; RFA–DA–
20–026: Targeting Inflammasomes in
Substance Abuse and HIV.
Date: March 12, 2020.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Dr., Bethesda,
MD 20892 (Virtual Meeting).
Contact Person: Tina McIntyre, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4202,
MSC 7812, Bethesda, MD 20892, 301–594–
6375, mcintyrt@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Fellowships: Cell Biology, Developmental
Biology, and Bioengineering.
Date: March 17–18, 2020.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Doubletree Hotel Bethesda
(Formerly Holiday Inn Select), 8120
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Alexander Gubin, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4196,
MSC 7812, Bethesda, MD 20892, 301–435–
2902, gubina@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Biological Chemistry, Biophysics,
and Assay Development.
Date: March 18–19, 2020.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Doubletree Hotel Bethesda
(Formerly Holiday Inn Select), 8120
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: John Harold Laity, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, 6701 Rockledge Drive,
Bethesda, MD 20892, 301–402–8254,
john.laity@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; BRAIN
Initiative: Targeted BRAIN Circuits Projects.
Date: March 18–19, 2020.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Washington Plaza Hotel, 10 Thomas
Circle NW, Washington, DC 20005.
Contact Person: Kirk Thompson, Ph.D.,
Scientific Review Officer, Center for
E:\FR\FM\20FEN1.SGM
20FEN1
]]>Agencies
[Federal Register Volume 85, Number 34 (Thursday, February 20, 2020)]
[Notices]
[Pages 9786-9787]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-03334]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; ZAI1-EC-D-M1, NIAID Research
Education Program (R25) Mar 31, 2020.
Date: March 31, 2020.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 5601 Fishers Lane,
Rockville, MD 20892 (Telephone Conference Call).
Contact Person: Eleazar Cohen, Ph.D., Scientific Review Officer,
Scientific Review Program, Division of Extramural Activities,
National Institute of Allergy and Infectious Diseases, National
Institute of Health, 5601 Fishers Lane, Room 3G62A, Bethesda, MD
20892, (240) 669-5081, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
[[Page 9787]]
Dated: February 13, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-03334 Filed 2-19-20; 8:45 am]
BILLING CODE 4140-01-P
